Navigation Links
David W. Keiser to Retire as President of Alexion
Date:11/11/2008

Co-Founder Remains On Board Of Directors

CHESHIRE, Conn., Nov. 11 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion," the "Company," Nasdaq: ALXN) announced today that David W. Keiser, the Company's Chief Operating Officer since 1992 and President since 2002, will retire by the end of 2008. Mr. Keiser, a co-founder of Alexion, played a central role in the commercial launch of Soliris(R) (eculizumab) in the United States and Europe, and helped to build a broad platform for continued growth in those and other territories. He will remain on Alexion's Board of Directors at least through the expiration of his current term in 2009 and will be available to consult with management and the Board in the future. Mr. Keiser's responsibilities will be distributed among current members of Alexion's senior management reporting to Leonard Bell, M.D., Chief Executive Officer of Alexion.

Mr. Keiser joined Alexion as Executive Vice President and Chief Operating Officer shortly after the Company was established in 1992, bringing to the start-up organization nearly 15 years of international experience with leading pharmaceutical companies including Hoffmann La Roche and G.D. Searle. At Alexion, he played a central role in managing the Company's manufacturing and regulatory efforts, and then initiated the establishment of the Company's commercial teams in the U.S. and Europe to support the 2007 launch of Soliris, the Company's first commercial product, a life-changing biopharmaceutical therapy for patients with paroxysmal nocturnal hemoglobinuria, a rare, debilitating and life-threatening disease.

"David is a unique individual and executive and I have enjoyed working with him as Alexion built its global organization. His top-level expertise and broad experience were instrumental in our evolution from the early group of scientists into an international organization that is now able to deliver Soliris to a growing number of patients in a growing
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. St. Davids HealthCare Launches The TIA Center for Stroke Prevention at St. Davids Medical Center
2. Ortiz to Host Celebrity Golf Tournament to Benefit The David Ortiz Childrens Fund
3. Aflac Celebrates With Petersons Harley Davidson of Miami as 100,000th Online Billing Customer
4. Sunrise Senior Living Appoints Glyn Aeppel and David Fuente to its Board
5. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures
6. Anpath Group, Inc. Announces Appointments of David V. Gilroy and Paul A. Boyer to Board of Directors
7. David B. Samadi, MD, Demonstrates Robotic Prostate Surgery During Live Webcast, August 13, 2008
8. Los Angeles Jewish Home Selects Community Volunteer David Swartz as its Board of Directors Chair
9. American Biosurgical Adds David Brazeal, CPA as Chief Financial Officer
10. Portable Endoscopic Company Announces Hiring of David Guy as COO/President
11. SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... of the commonly used stimulant methylphenidate (Ritalin) to speed ... the inhaled gas isoflurane, as previously reported, and to ... Massachusetts General Hospital (MGH) research team that reported the ... the May issue of Anesthesiology, and their ...
... HealthDay Reporter , THURSDAY, April 5 (HealthDay News) -- ... crops eaten by U.S. consumers is linked to shorter ... pesticides are known as organophosphates, which kill insects by ... nerve poisons during World War II, they can disrupt ...
... Serena Gordon HealthDay Reporter , THURSDAY, April 5 ... cells that potentially grow into tumors has been one of ... researchers from the Children,s Hospital of Philadelphia have generated a ... at least for stem cells destined for the digestive system ...
... largest multicenter clinical trial of children undergoing early-stage ... management did not significantly affect neurodevelopmental outcomes at ... were innate patient characteristics and general medical morbidity ... Children born with hypoplastic left-heart syndrome (HLHS) ...
... PhD, is the 2012 recipient of Kessler Foundation,s Joel A. ... the Field of Physical Medicine & Rehabilitation (PM&R). Dr. Whyte ... in West Orange on May 10. The award includes a ... Dr. Whyte is the founding director of Moss Rehabilitation ...
... Stem Cell , a Cell Press publication, have found a ... advance in mice suggests that a combination approach to therapy ... That,s in contrast to the vast majority of CML patients ... into remission only to see their cancer return again. It ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: